Hybrid Cell Membrane-Conjugated Photosensitive Hydrogel as a Tumor Vaccine for Promoting Cancer Immunotherapy

Key Points

• This research investigates the development of a hybrid tumor vaccine aimed at improving immune responses.
• Developed a photosensitive hydrogel conjugated with hybrid cell membranes.
• Evaluated the vaccine's ability to promote immune activation against tumors.
• Conducted experiments assessing clinical efficacy in a suitable model.
• The vaccine significantly enhanced immune activation compared to traditional approaches.
• Improvements in clinical efficacy were observed, indicating potential for better cancer immunotherapy outcomes.